Clinical Trial Detail

To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT02658214
Title	Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
Recruitment	Completed
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	AstraZeneca
Indications	peritoneum cancer fallopian tube cancer ovarian cancer triple-receptor negative breast cancer stomach cancer lung small cell carcinoma gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma
Therapies	Cisplatin + Durvalumab + Fluorouracil + Tremelimumab Durvalumab + Gemcitabine + Nab-paclitaxel + Tremelimumab Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin + Tremelimumab Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab Carboplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Durvalumab + Paclitaxel + Tremelimumab Carboplatin + Durvalumab + Gemcitabine + Tremelimumab
Age Groups:	adult \| senior
Covered Countries

Facility	City	Zip	Country	Details
Research Site	Chuo-ku	104-0045	Japan	Details
Research Site	Kashiwa	277-8577	Japan	Details
Research Site	Seoul	03080	Korea, Republic of	Details
Research Site	Seoul	03722	Korea, Republic of	Details
Research Site	Seoul	05505	Korea, Republic of	Details
Research Site	Seoul	135-710	Korea, Republic of	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field